85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

diseases per page:

Showing 1 to 10 of 627 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05571059 (ClinicalTrials.gov)	June 2023	27/9/2022	Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)	A Randomized, Double-Blind, Placebo-Controlled Phase II Study With an Open-Label Extension to Determ ...	Idiopathic Pulmonary Fibrosis	Drug: Ifetroban Sodium;Drug: Placebo	Cumberland Pharmaceuticals	NULL	Not yet recruiting	40 Years	80 Years	All	128	Phase 2	NULL
2	NCT05674994 (ClinicalTrials.gov)	March 15, 2023	9/12/2022	Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibro ...	Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibro ...	Acute Exacerbation of Idiopathic Pulmonary Fibrosis	Drug: Methylprednisone /Prednisone;Other: Placebo	Groupe Hospitalier Paris Saint Joseph	NULL	Not yet recruiting	18 Years	N/A	All	110	Phase 3	France
3	NCT05195918 (ClinicalTrials.gov)	March 1, 2023	2/12/2021	Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients	Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients Wi ...	Idiopathic Pulmonary Fibrosis	Combination Product: EGCG 300 mg + Nintedanib;Combination Product: EGCG 300 mg + Pirfenidone;Combina ...	Hal Chapman	University of Michigan;Cornell University;Massachusetts General Hospital;Temple University;Universit ...	Not yet recruiting	40 Years	85 Years	All	50	Phase 1	United States
4	NCT05671835 (ClinicalTrials.gov)	March 2023	3/1/2023	Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis	REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate th ...	Idiopathic Pulmonary Fibrosis	Drug: TTI-101;Drug: Placebo	Tvardi Therapeutics, Incorporated	NULL	Recruiting	40 Years	N/A	All	100	Phase 2	United States
5	NCT05349760 (ClinicalTrials.gov)	March 2023	31/3/2022	A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fib ...	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerabili ...	IPF	Biological: AMB-05X;Drug: Placebo	AmMax Bio, Inc.	NULL	Withdrawn	40 Years	N/A	All	0	Phase 2	NULL
6	NCT05483907 (ClinicalTrials.gov)	February 21, 2023	27/7/2022	To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF	A Phase 2, Randomized, Double-blind, Placebo-controlled, 24-Week Study to Evaluate the Efficacy, Saf ...	Idiopathic Pulmonary Fibrosis	Drug: BBT-877;Drug: Placebo	Bridge Biotherapeutics, Inc.	NULL	Recruiting	40 Years	N/A	All	120	Phase 2	United States;Australia;Israel
7	NCT05515627 (ClinicalTrials.gov)	February 15, 2023	12/8/2022	Atezolizumab for Idiopathic Pulmonary Fibrosis	A Phase I Study to Evaluate the Safety and Preliminary Efficacy of Atezolizumab in Idiopathic Pulmon ...	Idiopathic Pulmonary Fibrosis	Drug: Atezolizumab	Cedars-Sinai Medical Center	Genentech, Inc.	Recruiting	50 Years	80 Years	All	24	Phase 1	United States
8	NCT05722964 (ClinicalTrials.gov)	February 2023	11/1/2023	Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis	Efficacy and Safety of Intravenous Infusion of SHR-1906 in Patients With Idiopathic Pulmonary Fibros ...	Idiopathic Pulmonary Fibrosis	Drug: SHR-1906;Drug: Placebo	Guangdong Hengrui Pharmaceutical Co., Ltd	NULL	Not yet recruiting	40 Years	80 Years	All	108	Phase 2	NULL
9	NCT05537025 (ClinicalTrials.gov)	January 30, 2023	8/9/2022	Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fib ...	A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Pa ...	Idiopathic Pulmonary Fibrosis	Drug: ARO-MMP7 Inhalation Solution;Drug: Placebo	Arrowhead Pharmaceuticals	NULL	Recruiting	18 Years	N/A	All	77	Phase 1/Phase 2	New Zealand
10	EUCTR2022-001091-34-DK (EUCTR)	26/01/2023	13/12/2022	A study to find out whether BI 1015550 improves lung functionin people with Idiopathic Pulmonary Fib ...	A double blind, randomized, placebo-controlled trial evaluatingthe efficacy and safety of BI 1015550 ...	Idiopathic Pulmonary Fibrosis(IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: ...	Product Name: BI 1015550 9 mg Film Coated Tablet Product Code: BI 1015550 Other descriptive name: BI 10 ...	Boehringer Ingelheim France	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	963	Phase 3	Serbia;Portugal;United States;Saudi Arabia;Taiwan;Estonia;Greece;Spain;Thailand;Ukraine;Ireland;Russ ...

First Previous1 2 3 4 5…63Next Last